The US Food and Drug Administration has approved a new medicine for haemophilia B – the first treatment for the disorder to require less frequent injections. The drug, Alprolix, was developed by Biogen Idec Inc and Swedish Orphan Biovitrum AB.
Evotec AG has entered 2014 with a simplified structure that will highlight revenue from projects generated from the company’s own internal research. Going forward, the company will also use the financial metric, EBITA, as its main indicator for productivity.
More than six months into new management, Kymab Ltd is taking steps to build a pipeline of therapeutics that is based on a proprietary transgenic mouse platform.
A novel gene therapy developed by bluebird bio Inc of Cambridge, Massachusetts has been administered to a patient with beta-thalassemia, a rare blood disorder. The treatment involves an autologous haematopoietic stem cell transplantation.
Daratumumab, a candidate antibody therapeutic developed by Genmab A/S, has reached a second milestone under a collaboration with Janssen Biotech Inc triggering a $22 million payment to the Danish company. Daratumumab targets CD38.
Medigene AG has reported a sharply lower loss on higher revenue for 2013, a period during which it shifted its cancer focus to immunotherapies. During the year the company also expanded an out-licensing agreement to advance the development of EndoTAG-1.
Transgene SA, a developer of oncolytic virus therapies and an indirect subsidiary of the Institut Mérieux Group, has raised €65.5 million in a two-part share offering enabling it to carry forward an ambitious clinical trial programme for its portfolio of immunotherapies.
4SC AG, a small molecule developer with a service operation, reported increased revenues and a smaller loss for 2013 as a result of austerity measures. But its holding of cash and marketable securities at year-end declined sharply.
GlaxoSmithKline Plc has withdrawn its marketing authorisation application in Europe for the combination melanoma treatment trametinib/dabrafenib.
Nanobiotix SA, which produces nanoparticles designed to increase the efficacy of radiotherapy, has increased its capital with a €28.1 million offering on the NYSE Euronext Paris exchange. Proceeds will be used to advance its lead cancer agent – a medical device.